GSK in biopharma buy-out
Pharmaceuticals giant GlaxoSmithKline (GSK) is set to strengthen its drug discovery capacity as it pursues the acquisition of a US developer of proprietary, molecule drugs for the treatment of Type 2 Diabetes.
News
Pharmaceuticals giant GlaxoSmithKline (GSK) is set to strengthen its drug discovery capacity as it pursues the acquisition of a US developer of proprietary, molecule drugs for the treatment of Type 2 Diabetes.
News
News